Jurjen Luykx obtained his medical degree at Utrecht University in 2005. He was a visiting scholar and was trained in neurogenetics at the University of California, Los Angeles (UCLA) in 2006/2007. In 2012 he finished his residency in psychiatry and has since held several clinical consultant positions at psychiatric hospitals in Arnhem and the Utrecht area. Starting January 1st, 2013 he holds a staff position as a clinical psychiatrist and heads the emergency psychiatry unit at ZNA (Ziekenhuis Netwerk Antwerpen) in Antwerp, Belgium. In March 2013 he obtained his PhD in neuropsychiatric genetics at Utrecht University. His thesis was entitled ‘Determinants of neurotransmitters in cerebrospinal fluid and plasma’ and his supervisors were Professors Kahn and Ophoff. In this work he demonstrates how both hypothesis-driven and genome-wide approaches in healthy subjects deepen our understanding of endophenotypes relevant to the field of psychiatric genetics. Since January 1st, 2014 he has been heading the Psychiatric Genetics Program of the Human Neurogenetics Unit at the Brain Center Rudolf Magnus (BCRM). This dedicated research position and his clinical appointment at ZNA in Antwerp enable him to collect large datasets of patients and carry out next-generation sequencing (NGS) and other genotyping projects. The Human Neurogenetics Unit is headed by Professor Veldink, who has tremendous expertise in analyzing large datasets of genetic data, allowing several interdisciplinary genetic studies to be set up. Jurjen is country coordinator for several clinical trials in schizophrenia, e.g. a trial investigating predniolone augmentation in schizophrenia and EULAST (http://www.eulast.eu); he additionally leads the genetic part of that study (both whole-genome and targeted pharmacogenomics research topics). He is the daily supervisor of two PhD students and at the BCRM: one focuses on genetic pleiotropy and the other on the genetics of phenotypes related to clozapine use. He was awarded the Rudolf Magnus Young Talent Fellowship in December 2014, allowing him to perform additional targeted NGS projects in the near future. Postdoctoral researcher Raha Pazoki has been working under his supervision as of August 2015, focusing on NGS and GWAS projects. His current areas of focus include genetics of clozapine-related phenotypes, genetics of brain electrophysiologial measures, pharmacogenetics, genetic pleiotropy and cerebrospinal fluid research in psychiatry.